As research on the gut microbiome progresses, new types of bacteria beyond the mainstays Bifidobacterium and Lactobacillus are emerging as targets to enhance microbial health. Chief among this list is Akkermansia, a genus represented by the single species Akkermansia muciniphilia in humans. Akkermansia has been shown to play a beneficial role in gut barrier function and modulating human weight and metabolism.1 In addition, sufferers of disorders like obesity, Type 2 Diabetes, IBD and IBS have recorded depleted levels of Akkermansia.2
Efforts to stimulate the activity or enhance the abundance of this genus are actively being sought. While previous studies show that Akkermansia growth is associated with host health benefits, the magnitude of Akkermansia increase tends to be modest.3
Solnul™’s Low Dose Clinical Study revealed the highest reported increase in Akkermansia levels in a human clinical study with only 3.5 grams supplementation after 4 weeks. These findings suggest that formulators seeking to develop products for improved barrier function and leaky gut, and metabolic improvements like weight loss and blood glucose management can complement their formulations with 3.5 g of Solnul™, thereby supporting endogenous Akkermansia.